

Cc: [redacted] 5.1.2e [redacted] 5.1.2e @vhir.org; [redacted] 5.1.2e [redacted] 5.1.2e @rivm.nl; [redacted] 5.1.2e
 5.1.2e [redacted] 5.1.2e @genyo.es; [redacted] 5.1.2e [redacted] 5.1.2e @genyo.es
To: [redacted] 5.1.2e [redacted] 5.1.2e @rivm.nl
From: [redacted] 5.1.2e
Sent: Wed 4/27/2022 5:42:34 AM
Subject: Re: Post-flu patients
Received: Wed 4/27/2022 5:43:04 AM

Dear [redacted] 5.1.2e
 thanks for your e-mail and apologies I had misses/forgotten that email.

As for the presentation, of course we would be delighted to guide you though that or provide more information about the results.

Thanks for your help,

[redacted] 5.1.2e

[redacted] 5.1.2e
 [redacted] 5.1.2e
 Mucosal Immunology Lab, Universidad de Valladolid
 Instituto de Biomedicina y Genética Molecular (IBGM)
 [redacted] 5.1.2e Valladolid (47003). Spain
 Telephone: (0034) [redacted] 5.1.2e
 E-mail: [redacted] 5.1.2e @gmail.com / [redacted] 5.1.2e @uva.es
 Skype: [redacted] 5.1.2e @yahoo.es
 webpage:
<http://www.ibgm.med.uva.es/investigacion/inmunitad-innata-e-inflamacion/alergia-e-inmunitad-de-mucosas/>

El 26 abr 2022, a las 23:05, [redacted] 5.1.2e <[redacted] 5.1.2e @rivm.nl> escribió:

Dear [redacted] 5.1.2e

Thank you for your update, which is indeed a bit cryptic in view of the language.
 Regarding your question: I think I shared the information (known to us) on the flu cohort earlier (see email 21st December, and files sent via wetransfer), only 2 cases were hospitalized, the days are known (see table), not whether oxygen needed.
 I transferred the files a minute ago, again via wetransfer.

I hope this helps.
 If you have further questions please let me know.
 Kind regards,

[redacted] 5.1.2e

[redacted] 5.1.2e Vaccinology: Correlates of Protection | ^{1,2}
¹Centre for Immunology of Infectious Diseases and Vaccines | National Institute for Public Health and the Environment (RIVM) | Antonie van Leeuwenhoeklaan 9 | PO box 1 | 3720 BA BILTHOVEN | The Netherlands
²Infectious Diseases & Immunology | Dept. Biomolecular Health Sciences | Faculty of Veterinary Medicine | Utrecht University | Yalelaan 1 | PO box [redacted] 5.1.2e 3508 TD UTRECHT | The Netherlands
 T: +31 (0)30 [redacted] 5.1.2e E: [redacted] 5.1.2e @rivm.nl

Van: [redacted] 5.1.2e [redacted] 5.1.2e @gmail.com>

Verzonden: dinsdag 26 april 2022 18:09

Aan: [redacted] 5.1.2e [redacted] 5.1.2e @vhir.org>

CC: [redacted] 5.1.2e [redacted] 5.1.2e @rivm.nl>; [redacted] 5.1.2e [redacted] 5.1.2e @rivm.nl>; [redacted] 5.1.2e
 <[redacted] 5.1.2e @genyo.es>; [redacted] 5.1.2e <[redacted] 5.1.2e @genyo.es>

Onderwerp: Re: Post-flu patients

Dear 5.1.2e and 5.1.2e

hope you are ok. We have finally finished the analyses so we are now moving with the writing. We forward you the final results (apologies slides are in spanish so if you do not understand something feel free to ask).

Long story short, post-flue and pre pandemic controls behave pretty similar, while the post-COVID move away from them. Besides, we can see two clear clusters in the post-COVID, being the most different one enriched in younger patients.

We were now discussing how to organize the tables/figures etc. and we had a doubt. Could you please forward us, if you have the information, i) if patients had been in hospital and, if so, the number of day and/or O2 need; and ii) days when the sample was obtained after the diagnose?

With kind regards,

5.1.2e

5.1.2e
5.1.2e
Mucosal Immunology Lab, Universidad de Valladolid
Unidad de Excelencia Instituto de Biología y Genética Molecular (IBGM)
5.1.2e Valladolid (47003). Spain
Telephone: (0034) 5.1.2e
E-mail: 5.1.2e @gmail.com / 5.1.2e @uva.es
webpage: <http://www.ibgm.med.uva.es/investigacion/inmunidad-innata-e-inflamacion/alergia-e-inmunidad-de-mucosas>

El 19 abr 2022, a las 12:09, 5.1.2e <5.1.2e@gmail.com> escribió:

And now with 5.1.2e and 5.1.2e in CC, apologies.

Ta,

5.1.2e

5.1.2e
5.1.2e
Mucosal Immunology Lab, Universidad de Valladolid
Unidad de Excelencia Instituto de Biología y Genética Molecular (IBGM)
5.1.2e Valladolid (47003). Spain
Telephone: (0034) 5.1.2e
E-mail: 5.1.2e @gmail.com / 5.1.2e @uva.es
webpage: <http://www.ibgm.med.uva.es/investigacion/inmunidad-innata-e-inflamacion/alergia-e-inmunidad-de-mucosas>

El 19 abr 2022, a las 12:08, 5.1.2e <5.1.2e@gmail.com> escribió:

Ps.

attached you can find guys the presentation that 5.1.2e did in Granada only focused in pre-pandemic control and post-COVID

I'm also attaching the work in progress overview from yesterday. Slide 3 is quite representative as you can see how post-flu and pre-pandemic controls merge together and apart from the post-COVID. We had included a second cohort of non-COVID controls who attended the hospital, but given their cytokine levels we will ignore them and focus on the 3 original cohorts (pre-pandemic controls, post-COVID and pot-flu).

Please let us know if you want/need any further input at this stage.

Regards,

5.1.2e

<Resultados post-COVID 180422.pptx>

<Oral_JJCC_Genyo_21_FPC.pptx>

5.1.2e

5.1.2e

Mucosal Immunology Lab, Universidad de Valladolid
Unidad de Excelencia Instituto de Biología y Genética Molecular (IBGM)
5.1.2e Valladolid (47003), Spain

Telephone: (0034)

5.1.2e

E-mail: 5.1.2e @gmail.com / 5.1.2e @uva.es

webpage: <http://www.ibgm.med.uva.es/investigacion/inmunidad-innata-e-inflamacion/alergia-e-inmunidad-de-mucosas>

El 12 abr 2022, a las 17:21, 5.1.2e

< 5.1.2e @vhir.org> escribió:

Hola 5.1.2e

How are you doing? Hope you're well!

I talked to 5.1.2e today and we were wondering how the project is going. Also, we were wondering if we could see the presentation that was presented at the conference in Granada if that's possible? The conference in Seattle is still coming up right? so I guess there is no presentation for us to see on that yet. Otherwise, is there a draft we could already look at, or is that too early at this point? This to interpret the findings in the Influenza samples to your data and to see what steps we could take with the influenza data.

Again, hope you're well and all the best,

5.1.2e

Van: 5.1.2e < 5.1.2e @rivm.nl>

Verzonden: donderdag 23 december 2021 11:21

Aan: 5.1.2e

CC: 5.1.2e

Onderwerp: RE: Post-flu patients

Thanks 5.1.2e

Happy holidays!

5.1.2e

5.1.2e

Vaccinology: Correlates of Protection | ^{1,2}

¹ Centre for Immunology of Infectious Diseases and Vaccines | National Institute for Public Health and the Environment (RIVM) | Antonie van Leeuwenhoeklaan 9 | PO box 1 | 3720 BA BILTHOVEN | The Netherlands

² Infectious Diseases & Immunology | Dept. Biomolecular Health Sciences | Faculty of Veterinary Medicine | Utrecht University | Yalelaan 1 | PO box 5.1.2e 3508 TD UTRECHT | The Netherlands
T: +31 (0)30 5.1.2e E: 5.1.2e @rivm.nl

Van: 5.1.2e <5.1.2e@gmail.com>
 Verzonden: donderdag 23 december 2021 11:01
 Aan: 5.1.2e <5.1.2e@rivm.nl>
 CC: 5.1.2e <@vhir.org>
 Onderwerp: Re: Post-flu patients

Hi 5.1.2e

for the time being we would like to send a draft to all the authors by the end of January so do not worry as you will have plenty of time for that...

All the best,

5.1.2e

5.1.2e
 5.1.2e
 Mucosal Immunology Lab, Universidad de Valladolid
 Instituto de Biomedicina y Genética Molecular (IBGM)
 5.1.2e Valladolid (47003). Spain
 Telephone: (0034) 5.1.2e
 E-mail: 5.1.2e@gmail.com / 5.1.2e@uva.es
 Skype: 5.1.2e@yahoo.es
 webpage:
<http://www.ibgm.med.uva.es/investigacion/inmunidad-innata-e-inflamacion/alergia-e-inmunidad-de-mucosas/>
<https://investiga.uva.es/atraccion-talento-uva/ramon-y-cajal/david-bernardo/>

El 22 dic 2021, a las 16:20, 5.1.2e
 <5.1.2e@rivm.nl> escribió:

Hi 5.1.2e

Thanks for the update.
 Regarding publication of a manuscript, could you indicate which timelines you have in mind?
 This, in view of holiday planning as well as the fact that I need to comply to some sort of publication-permission-procedure here at our end.
 If there is a preliminary but complete draft I could use that to set things in working here.

Kind regards, 5.1.2e

5.1.2e Vaccinology: Correlates of Protection | ^{1,2}
¹ Centre for Immunology of Infectious Diseases and Vaccines | National Institute for Public Health and the Environment (RIVM) | Antonie van Leeuwenhoeklaan 9 | PO box 1 | 3720 BA BILTHOVEN | The Netherlands
² Infectious Diseases & Immunology | Dept. Biomolecular Health Sciences | Faculty of Veterinary Medicine | Utrecht University | Yalelaan 1 | PO box 5.1.2e 3508 TD UTRECHT | The Netherlands
 T: +31 (0)30 5.1.2e | E: 5.1.2e@rivm.nl

Van: 5.1.2e <5.1.2e@gmail.com>
 Verzonden: woensdag 22 december 2021 15:13
 Aan: 5.1.2e <5.1.2e@rivm.nl>
 CC: 5.1.2e <@vhir.org>
 Onderwerp: Re: Post-flu patients

Dear 5.1.2e

thanks for your quick and kind response. Same story here I am afraid as we are also overwhelmed. Really looking for a Xmas break although will have to write 3 projects (deadlines in early January) so not sure that I shall be able to fully disconnect...

As for your e-mail and the WeTransfer, have just forwarded it to 5.1.2e my postdoc. Thanks. Once we have a look at the data we will let you know if we need any more information although given that the main cohort is the COVID one, I am sure that we shall not need much more information. Also, we have been talking with a JEM editor and she thinks that the paper could fit in the journal so that will be our first shoot.

All the best,

5.1.2e

5.1.2e

5.1.2e

Mucosal Immunology Lab, Universidad de Valladolid
Unidad de Excelencia Instituto de Biología y Genética Molecular (IBGM)
5.1.2e Valladolid (47003). Spain

Telephone: (0034

5.1.2e

E-mail:

5.1.2e

@gmail.com /

5.1.2e

@uva.es

webpages:

<http://www.ibgm.med.uva.es/investigacion/inmunidad-innata-e-inflamacion/alergia-e-inmunidad-de-mucosas>

<https://investiga.uva.es/atraccion-talento-uva/ramon-y-cajal/david-bernardo/>

El 21 dic 2021, a las 21:21, 5.1.2e

< 5.1.2e @rivm.nl> escribió:

Dear 5.1.2e

Thank you I'm well, although undersnowed by a continuous stream of questions from government, general public and media about the pandemic, variants of concern, non-pharmaceutical measures (near lockdown again) and vaccination programme! I hope you are also doing well.

The influenza cohort is associated with a GP sentinel network in the Netherlands that in the flu season weekly sends in diagnostics nose swabs from a random fraction of their patients presenting in their general practices with ILI symptoms. The samples are then

tested molecularly at the RIVM for general seasonal viruses, and Influenza A positives were the recruitment population for candidate participants of our Immfact study. Participants are included in the study during housevisits, which is when samples (blood for PBMCs and serum, as well as saliva) are taken for the lab. We actually take samples longitudinally (over three years), as we are interested in biobanking PBMC to study dynamics of effector and memory immunity and T cell specificity. The first sample, the one you received, is per protocol taken within 3 months after diagnosis. On average this was 71 days after diagnosis for these 25 participants (which was on average 7 days after 1st symptoms).

Separately (via we-transfer... in view of patients data a somehow pass-word secured transfer) I'll send you some more information on the cohort (a Materials and Methods-type section, and a table giving more info on the time of sampling, duration of symptoms and whether or not hospitalized) (Note, there were 2 cases hospitalized.)

Depending on the kind of information needed for the demographics table, we can look up more metadata on type of symptoms (see Methods section).

This will not be possible before holidays I think because the department is fully busy with covid studie right now.

I hope this helps.

If you have further questions please let me know.

Kind regards,

5.1.2e

5.1.2e Vaccinology: Correlates of Protection | ^{1,2}

¹Centre for Immunology of Infectious Diseases and Vaccines | National Institute for Public Health and the Environment (RIVM) | Antonie van Leeuwenhoeklaan 9 | PO box 1 | 3720 BA BILTHOVEN | The Netherlands

²Infectious Diseases & Immunology | Dept. Biomolecular Health Sciences | Faculty of Veterinary Medicine | Utrecht University | Yalelaan 1 | PO box 5.1.2e 3508 TD UTRECHT | The Netherlands
T: +31 (0)30 5.1.2e E: 5.1.2e @rivm.nl

Van: 5.1.2e
<5.1.2e@gmail.com>

Verzonden: maandag 20 december 2021 17:22

Aan: 5.1.2e @vhir.org; 5.1.2e

<5.1.2e@rivm.nl>

Onderwerp: Post-flu patients

Hello there,

hope both of you guys are doing fine. I am writing you because we are preparing the tables with the

demographic information of the patients, and we have just noticed that regarding the post-flu cohort, we only have information about gender and age.

Did all the patients were hospitalized or it was not the case? Also, could you please forward us the information relating how many days passed after hospital discharge of post-infection until the moment when the samples were taking. Finally, Is there any more information that you consider that we should add?

All the best,

5.1.2e

5.1.2e

5.1.2e

Mucosal Immunology Lab, Universidad de Valladolid
Unidad de Excelencia Instituto de Biología y Genética
Molecular (IBGM)

5.1.2e

Valladolid

(47003). Spain

Telephone: (0034)

5.1.2e

E-

mail: 5.1.2e @gmail.com / 5.1.2e @uva.es

webpages:

<http://www.ibgm.med.uva.es/investigacion/inmunidad-innata-e-inflamacion/alergia-e-inmunidad-de-mucosas>

<https://investiga.uva.es/atraccion-talento-uva/ramon-y-cajal/david-bernardo/>

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.

www.rivm.nl De zorg voor morgen begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.

www.rivm.nl/en Committed to health and sustainability

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen.

Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.

www.rivm.nl *De zorg voor morgen begint vandaag*

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.

www.rivm.nl/en *Committed to health and sustainability*

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.

www.rivm.nl *De zorg voor morgen begint vandaag*

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.

www.rivm.nl/en *Committed to health and sustainability*

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.

www.rivm.nl *De zorg voor morgen begint vandaag*

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.

www.rivm.nl/en *Committed to health and sustainability*